Abstract

Dr. Vaishali*, Dr. Manoj Kumar, Dr. Ashu

ABSTRACT

Background: Ardhavabhedaka is one of the eleven Shirorogas described by Acharya Sushruta and is characterized by recurrent unilateral headache associated with severe pain. The clinical presentation closely resembles migraine, one of the most prevalent primary headache disorders worldwide. Migraine considerably affects the quality of life and is frequently associated with nausea, vomiting, photophobia, phonophobia and aura. Although several modern pharmacological therapies are available, long-term treatment is often associated with recurrence, adverse drug reactions and incomplete symptomatic relief. Ayurveda advocates Nasya Karma as the principal therapeutic intervention for diseases of Urdhwajatru, while Pathyadi Kwath is a classical formulation indicated for Shiroroga. Comparative evidence regarding the efficacy of Manjishthadi Taila Nasya and Anu Taila Nasya in migraine is limited, necessitating systematic clinical evaluation. Objective: To evaluate and compare the efficacy of Manjishthadi Taila Nasya and Anu Taila Nasya administered along with Pathyadi Kwath in the management of Ardhavabhedaka (Migraine). Methods: A randomized, open-labelled, controlled clinical trial will be conducted on 60 patients (30 in each group) diagnosed with Ardhavabhedaka (Migraine), aged 18–60 years. Participants will be randomly allocated into two equal groups using computer-generated randomization. Group A will receive Manjishthadi Taila Marsha Nasya along with Pathyadi Kwath, whereas Group B will receive Anu Taila Marsha Nasya along with Pathyadi Kwath for 35 days. Nasya Karma will be administered in three sittings of seven days each with an interval of seven days. Clinical assessment will be performed using subjective symptom scores, Visual Analogue Scale (VAS), and appropriate laboratory investigations. Data will be analysed using suitable statistical methods, considering p < 0.05 as statistically significant. Expected Results: Both treatment protocols are anticipated to reduce the severity, frequency and duration of migraine attacks, along with associated symptoms including nausea, vomiting, photophobia, phonophobia, vertigo and aura. Manjishthadi Taila Nasya is hypothesized to demonstrate comparatively superior therapeutic efficacy because of its Tridoshaghna, Vata-Kaphahara and Shiroshoolahara properties. Conclusion: The present study is expected to generate scientific evidence regarding the comparative efficacy of Manjishthadi Taila Nasya and Anu Taila Nasya as adjuncts to Pathyadi Kwath in the management of Ardhavabhedaka (Migraine). The findings may contribute to evidence-based Ayurvedic management of migraine and encourage wider clinical application of Nasya therapy.